Skip to main content
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. — Investor Relations & Filings

Ticker · OKUR ISIN · US75974E1038 US Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2026-04-24 Capital/Financing Update
Country US United States of America
Listing US OKUR

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com/

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for cancer patients. The company is building a pipeline of potentially best-in-class, tumor-agnostic therapies that target biologically validated drivers of cancers, particularly those underserved by current treatments. Its research and development efforts are centered on novel and potentially less toxic kinase inhibitor drugs and epigenetic therapies.

Recent filings

Filing Released Lang Actions
S-3 - OnKure Therapeutics, Inc. (0001637715) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering. It includes detailed information about the securities being registered, the selling stockholders, and the terms of the offering. The document is not an earnings release, annual report, or any other financial report but a capital markets filing related to fundraising and securities registration. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full registration statement, not just an announcement or notice.
2026-04-24 English
8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a securities purchase agreement (private placement financing), registration rights agreement, election of a new director to the board, and updates on clinical programs. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. Instead, it focuses on financing activities and management changes. The presence of a new director election and financing agreement points to a combination of Capital/Financing Update and Board/Management Information. However, since the primary focus is on the securities purchase agreement and private placement financing, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement but a substantive filing. Therefore, the filing type code is CAP with high confidence.
2026-03-30 English
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
Director's Dealing
2026-03-24 English
4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
Director's Dealing
2026-03-24 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.